Results 21 to 30 of about 28,829 (241)

Evaluation of a Novel FKS1 R1354H Mutation Associated with Caspofungin Resistance in Candida auris Using the CRISPR-Cas9 System

Journal of Fungi, 2023
Outbreaks of invasive infections, with high mortality rates, caused by multidrug-resistant Candida auris have been reported worldwide. Although hotspot mutations in FKS1 are an established cause of echinocandin resistance, the actual contribution of ...
Maiko Kiyohara, T. Miyazaki, Michiyo Okamoto, T. Hirayama, K. Makimura, H. Chibana, Nana Nakada, Y. Ito, Makoto Sumiyoshi, N. Ashizawa, K. Takeda, N. Iwanaga, T. Takazono, K. Izumikawa, K. Yanagihara, S. Kohno, H. Mukae   +16 more
semanticscholar   +1 more source

Caspofungin [PDF]

Clinical Infectious Diseases, 2003
Caspofungin, the first inhibitor of fungal beta-1,3 glucan synthesis to receive approval by the United States Food and Drug Administration, is effective for the treatment of mucosal and invasive candidiasis and invasive aspergillosis. It is also active in vitro and in animal models against a number of other filamentous and dimorphic endemic fungi and ...
Louis D. Saravolatz, Stanley C. Deresinski, David A. Stevens   +2 more
openaire   +2 more sources

Gross karyotypic and phenotypic alterations among different progenies of the candida glabrata cbs138/atcc2001 reference strain [PDF]

, 2012
Peer reviewedPublisher ...
Bader, Oliver, De Groot, Piet W J, Gross, Uwe, Jacobsen, Mette D, Kraneveld, Eefje A, Schmidt, Pia, Schwarz, Alexander, Tangwattanchuleeporn, Marut, Weig, Michael   +8 more
core   +12 more sources

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi

bioRxiv, 2022
Current treatment of fungal infections is threatened by emerging antifungal drug resistance. In this work, the authors explore the synergistic activity of a host defense peptide mimetic, brilacidin, with caspofungin against a panel of fungal strains ...
Thaila Fernanda dos Reis, Patrícia Alves de Castro, R. W. Bastos, C. Pinzan, P. F. Souza, S. Ackloo, M. A. Hossain, D. Drewry, Sondus Alkhazraji, A. Ibrahim, Hyunil Jo, W. DeGrado, G. Goldman   +12 more
semanticscholar   +1 more source

Caspofungin Affects Extracellular Vesicle Production and Cargo in Candida auris

Journal of Fungi, 2022
Antifungal resistance has become more frequent, either due to the emergence of naturally resistant species or the development of mechanisms that lead to resistance in previously susceptible species.
R. Amatuzzi, Daniel Zamith-Miranda, I. F. Munhoz da Rocha, A. C. Lucena, Sharon de Toledo Martins, R. Streit, C. Staats, Gabriel Trentin, Fausto Almeida, M. Rodrigues, J. Nosanchuk, Lysangela R Alves   +11 more
semanticscholar   +1 more source

Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality. [PDF]

, 2020
Metabolic adaptation is linked to the ability of the opportunistic pathogen Candida albicans to colonize and cause infection in diverse host tissues. One way that C.
Filler, Scott G, Huang, Manning Y, Lagree, Katherine, May, Gemma, McManus, C Joel, Mitchell, Aaron P, Solis, Norma V, Woolford, Carol A   +7 more
core   +3 more sources

Development of Antifungal Peptides against Cryptococcus neoformans; Leveraging Knowledge about the cdc50Δ Mutant Susceptibility for Lead Compound Development

Microbiology Spectrum, 2022
Cryptococcus neoformans is a major fungal pathogen that often causes life-threatening meningitis in immunocompromised populations. This yeast pathogen is highly resistant to the echinocandin drug caspofungin.
Robert J. Tancer, Yina Wang, Siddhi Pawar, Chaoyang Xue, Gregory R. Wiedman   +4 more
doaj   +1 more source

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

Clinical Infectious Diseases, 2020
Background Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS ...
G. Thompson, Á. Soriano, A. Skoutelis, J. Vázquez, P. Honore, J. Horcajada, H. Spapen, M. Bassetti, L. Ostrosky-Zeichner, Anita F. Das, R. Viani, T. Sandison, P. Pappas   +12 more
semanticscholar   +1 more source

Puf4 Mediates Post-transcriptional Regulation of Cell Wall Biosynthesis and Caspofungin Resistance in Cryptococcus neoformans

mBio, 2021
Cryptococcus neoformans is an environmental fungus that causes pulmonary and central nervous system infections. It is also responsible for 15% of AIDS-related deaths.
Murat C. Kalem, H. Subbiah, Jay Leipheimer, Virginia E Glazier, J. Panepinto   +4 more
semanticscholar   +1 more source

Candida albicans Strains Adapted to Caspofungin Due to Aneuploidy Become Highly Tolerant under Continued Drug Pressure

Microorganisms, 2022
Candida albicans is a prevalent fungal pathogen of humans. Understanding the development of decreased susceptibility to ECN drugs of this microbe is of substantial interest, as it is viewed as an intermediate step allowing the formation of FKS1 ...
Farha Husain, Anshuman Yadav, Sudisht K. Sah, Jeffrey J. Hayes, Elena Rustchenko   +4 more
doaj   +1 more source